Pentazocine-naloxone experimenters among abusers of pentazocine and tripelennamine from a VA treatment population.
Psychiatric diagnostic profiles, drug and personal histories, and social support measures were obtained for a clinic sample of abusers of pentazocine when the drug was withdrawn and re-released by the manufacturer compounded with the opiate antagonist naloxone. Nearly 50% of the sample (N = 99) reported using the new drug during the following 6 to 9 months, despite its reduced abuse potential. Reinterviews revealed that claimed use of pentazocine dropped to half.